Welcome to our dedicated page for Liquidia Corporation SEC filings (Ticker: LQDA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Liquidia Corporation filings document a Delaware biopharmaceutical issuer reporting on YUTREPIA commercialization, treprostinil products and pulmonary hypertension programs. Form 8-K reports furnish quarterly and annual financial results, Regulation FD disclosures, corporate updates and investor presentation materials tied to PAH, PH-ILD, PRINT® Technology and the company’s product portfolio.
The filing record also covers governance and capital-market disclosure subjects, including definitive proxy materials, officer appointments and material definitive agreements. Recent agreement disclosures include the Liquidia Technologies licensing arrangement with Vectura for L606 and a nebulizer device in hypertension and interstitial lung disease treatment fields.
Liquidia Corp's Chief Medical Officer, Dr. Rajeev Saggar, reported new equity awards. He received 32,955 restricted stock units (RSUs) that convert into common stock on a one-for-one basis. According to the vesting schedule, 25% of these RSUs vest on January 11, 2027, with 6.25% vesting every three months thereafter.
Following this grant and prior awards, Dr. Saggar beneficially owns 209,838 shares of common stock, including unvested RSUs and shares acquired under the 2020 Employee Stock Purchase Plan. He was also granted 49,433 performance stock units (PSUs) that convert into common stock one-for-one. These PSUs vest 25% on the Initial Vesting Date or when the company files its Form 10-K for the year ending December 31, 2026, with additional 6.25% vesting quarterly, subject to a milestone based on 2026 net product sales revenue from YUTREPIA as disclosed in that Form 10-K.
Liquidia Corp’s general counsel, Russell Schundler, reported new equity awards and updated holdings. On January 16, 2026, he was granted 32,955 restricted stock units (RSUs) that convert into common stock on a one-for-one basis. These RSUs vest with 25% vesting on January 11, 2027, then 6.25% every three months after that.
He was also granted 49,433 performance stock units (PSUs), each convertible into one share of common stock. The PSUs vest 25% on the same initial vesting date (or, if later, when the company files its Form 10-K for 2026) and 6.25% every three months thereafter, subject to a milestone based on 2026 net product sales revenue from YUTREPIA as disclosed in the FY2026 Form 10-K. Following these grants, he beneficially owns 612,349 shares of common stock directly and 49,433 PSUs, plus 14,500 shares held indirectly by his spouse, for which he disclaims beneficial ownership except to the extent of his pecuniary interest.
Liquidia Corp's Chief Human Resource Officer, Sarah Krepp, reported equity compensation activity and a related share sale. On January 9, 2026, 12,716 performance stock units converted into the same number of common shares at an exercise price of $0, increasing her directly held common stock to 153,934 shares and leaving 38,145 derivative securities beneficially owned. On January 12, 2026, she sold 13,165 common shares at $37.43 per share, primarily to cover taxes tied to the settlement of RSUs and PSUs granted in 2024 and 2025 under company plans. After these transactions, she directly held 140,769 common shares, alongside sizable unvested RSU and PSU awards that continue to vest over time.
Liquidia Corp’s Chief Commercial Officer, Scott Moomaw, reported stock activity involving performance stock units (PSUs) and common shares. On January 9, 2026, PSUs converted into 3,108 and 17,433 shares of common stock at an exercise price of $0, reflecting vesting of prior PSU awards that convert into common stock on a one-for-one basis. Following these conversions, he held 175,047 shares directly. On January 12, 2026, he sold 20,533 common shares at $37.43 per share, leaving 154,514 shares held directly. According to the disclosure, this sale was executed under a pre-arranged Rule 10b5-1 trading plan adopted on December 15, 2023 and the shares were sold to cover taxes tied to the settlement of restricted stock units granted in 2023, 2024, and 2025.
Liquidia Corp executive Michael Kaseta, the CFO and COO, reported equity award vesting and a related stock sale. On January 9, 2026, performance stock units converted into 5,828 and 28,200 shares of Liquidia common stock on a one-for-one basis. These conversions stem from PSU grants made in 2024 and 2025 that vest over several years.
On January 12, 2026, Kaseta sold 36,932 shares of common stock at $37.43 per share, with ownership listed as direct and 350,919 shares beneficially owned afterward. The sale was executed under a Rule 10b5-1 trading plan adopted on December 15, 2023, and the shares were sold to cover taxes associated with the settlement of restricted and performance stock units from multiple prior grant dates.
Liquidia Corp Chief Business Officer Jason Adair reported equity award vesting and a related share sale. On January 9, 2026, performance stock units and restricted stock units converted into several blocks of common stock, including 3,906, 2,474 and 15,474 shares, as part of previously granted RSU and PSU awards that vest over multi‑year schedules.
On January 12, 2026, Adair sold 13,548 shares of common stock at $37.43 per share in a transaction carried out under a pre‑arranged Rule 10b5‑1 plan adopted on December 15, 2023. According to the disclosure, these shares were sold to cover taxes tied to the settlement of RSUs and PSUs granted in 2023, 2024 and 2025. After these transactions, Adair directly held 184,174 shares of Liquidia common stock, along with additional unvested RSUs and PSUs.
Liquidia Corp (LQDA) General Counsel Russell Schundler reported equity award vesting and a related share sale. On January 9, 2026, performance stock units converted into 3,759 and 25,636 shares of common stock at an exercise price of $0 per share, increasing his directly held common stock to 606,683 shares. On January 12, 2026, he sold 27,289 shares of common stock at $37.43 per share under a Rule 10b5-1 trading plan adopted on December 15, 2023, primarily to cover taxes tied to RSU and PSU settlements, leaving 579,394 shares held directly. The filing also notes an additional 14,500 shares held indirectly by his spouse, for which he disclaims beneficial ownership except to the extent of any pecuniary interest.
Liquidia Corp’s Chief Executive Officer and director Roger Jeffs reported equity award vesting and a related stock sale. On January 9, 2026, performance stock units converted into 13,833 and 57,332 shares of common stock, reflecting previously granted PSUs that vest over multi-year schedules. The filing notes that PSUs convert into common stock on a one-for-one basis.
On January 12, 2026, Jeffs sold 66,610 shares of Liquidia common stock at $37.43 per share in a transaction effected under a pre-established Rule 10b5-1 plan. According to the footnotes, these shares were sold to cover taxes tied to the settlement of RSUs and PSUs granted in 2023, 2024 and 2025. After these transactions, he directly held 1,037,528 common shares, with additional indirect holdings through a living trust and Serendipity BioPharma LLC.
Liquidia Corp’s Chief Accounting Officer, Dana Boyle, reported routine equity transactions. On January 9, 2026, 12,716 performance stock units converted into the same number of shares of common stock at an exercise price of $0, reflecting scheduled PSU vesting. On January 12, 2026, Boyle sold 11,047 shares of common stock at $37.43 per share, leaving 156,700 common shares beneficially owned afterward. The sale was made under a pre‑arranged Rule 10b5‑1 plan and was used to cover taxes tied to the settlement of previously granted RSUs and PSUs. Following these transactions, Boyle continued to hold 38,145 performance stock units in addition to other unvested equity awards.
Liquidia Corp Chief Medical Officer Dr. Rajeev Saggar reported equity award activity and a related share sale. On January 9, 2026, performance stock units (PSUs) converting on a one-for-one basis were settled into 3,531 and 17,945 shares of common stock at an exercise price of $0, increasing his directly held common stock to 198,025 shares. On January 12, 2026, he sold 21,142 shares of common stock at $37.43 per share, leaving 176,883 shares held directly afterward. The footnotes state this sale was effected under a Rule 10b5-1 trading plan adopted on December 15, 2023 and that the shares were sold to cover taxes associated with the settlement of equity awards granted in 2023, 2024 and 2025.